Deep Dive on Market Access

Deep Dive

Views & Analysis

A year on: pandemic driven trends in HCP engagement

IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19.

Views & Analysis

Deep Dive: Market Access

It’s fair to say this is the most interesting time ever for market access.

Views & Analysis

Breaking barriers to patient access in rare oncology

As technological advances unlock a more nuanced understanding of disease – and exciting opportunities for personalised medicine – some cancers are now being redefined as rare diseases.

Views & Analysis

Janssen: ‘Open dialogue’ needed with HTAs to improve access

The world of life sciences is changing rapidly, and the traditional ways of assessing drugs may no longer be fit for purpose.

Views & Analysis

A novel approach to detecting Alzheimer’s early

The grey matter in the brain may hold vital clues for early, accurate detection in Alzheimer’s, and potentially also help pharma to find new drug treatments.

Views & Analysis

Improving access and reimbursement for specialty therapies

As specialty therapies move toward long-term maintenance use and as treatment times grow longer, government and commercial payers are scrutinising the economic value of new treatments more

A year on: pandemic driven trends in HCP engagement

Deep Dive: Market Access

Breaking barriers to patient access in rare oncology

Janssen: ‘Open dialogue’ needed with HTAs to improve access

A novel approach to detecting Alzheimer’s early

Improving access and reimbursement for specialty therapies

DNA testing can help right racial imbalance in breast cancer

Using AI-driven synthetic personas to take your insights fur...

Deep Dive

Editor's Picks